CN107074849A - 新的化合物 - Google Patents

新的化合物 Download PDF

Info

Publication number
CN107074849A
CN107074849A CN201580051539.2A CN201580051539A CN107074849A CN 107074849 A CN107074849 A CN 107074849A CN 201580051539 A CN201580051539 A CN 201580051539A CN 107074849 A CN107074849 A CN 107074849A
Authority
CN
China
Prior art keywords
compound
fluoro
pharmaceutically acceptable
formula
bases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580051539.2A
Other languages
English (en)
Chinese (zh)
Inventor
N.A.安德森
M.H.J.坎贝尔-克劳福德
A.P.汉考克
J.M.普里查德
J.M.雷德蒙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of CN107074849A publication Critical patent/CN107074849A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN201580051539.2A 2014-09-26 2015-09-22 新的化合物 Pending CN107074849A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1417011.2A GB201417011D0 (en) 2014-09-26 2014-09-26 Novel compounds
GB1417011.2 2014-09-26
PCT/EP2015/071777 WO2016046226A1 (en) 2014-09-26 2015-09-22 Novel compounds

Publications (1)

Publication Number Publication Date
CN107074849A true CN107074849A (zh) 2017-08-18

Family

ID=51901167

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580051539.2A Pending CN107074849A (zh) 2014-09-26 2015-09-22 新的化合物

Country Status (15)

Country Link
US (1) US10000489B2 (https=)
EP (1) EP3197893B1 (https=)
JP (1) JP6665169B2 (https=)
KR (1) KR20170063590A (https=)
CN (1) CN107074849A (https=)
AR (1) AR101995A1 (https=)
AU (1) AU2015320859A1 (https=)
BR (1) BR112017006253A2 (https=)
CA (1) CA2962326A1 (https=)
ES (1) ES2704525T3 (https=)
GB (1) GB201417011D0 (https=)
RU (1) RU2017114346A (https=)
TW (1) TW201629057A (https=)
UY (1) UY36315A (https=)
WO (1) WO2016046226A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107823208A (zh) * 2017-10-25 2018-03-23 南京多宝生物科技有限公司 吗啉类化合物在制备治疗和预防肾纤维化药物中的应用
CN108208177A (zh) * 2017-11-28 2018-06-29 上海交通大学医学院附属新华医院 含丁酸类化合物的组合物及其应用

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201604680D0 (en) * 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604681D0 (en) * 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
WO2018089353A1 (en) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company 3-substituted propionic acids as alpha v integrin inhibitors
KR102506327B1 (ko) 2016-11-08 2023-03-03 브리스톨-마이어스 스큅 컴퍼니 αV 인테그린 길항제로서의 인다졸 유도체
SI3538528T1 (sl) 2016-11-08 2021-03-31 Bristol-Myers Squibb Company Pirol amidi kot alfa v integrin inhibitorji
MX2019005234A (es) 2016-11-08 2019-08-12 Squibb Bristol Myers Co Amidas y aminas de azol como inhibidores de integrina alfa v.
AU2017359025A1 (en) 2016-11-08 2019-06-20 Bristol-Myers Squibb Company Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha V integrin inhibitors
USRE50554E1 (en) 2016-12-23 2025-08-26 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
MA52117A (fr) 2017-02-28 2022-04-06 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
MA47697A (fr) 2017-02-28 2020-01-08 Morphic Therapeutic Inc Inhibiteurs de l'(alpha-v)(bêta-6) intégrine
ES2904645T3 (es) 2017-11-07 2022-04-05 Bristol Myers Squibb Co Derivados de pirrolopirazina como inhibidores de integrina alfa v
EP4086254B1 (en) 2018-08-29 2024-12-18 Morphic Therapeutic, Inc. Integrin inhibitors
FI3844162T3 (fi) 2018-08-29 2025-03-27 Morphic Therapeutic Inc Alfa v beeta6 -integriinin estäjiä
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
TW202028179A (zh) * 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
JP2022512648A (ja) * 2018-10-09 2022-02-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 心筋線維化の処置のためのαＶ－インテグリン（ＣＤ５１）阻害剤の使用
US11034710B2 (en) * 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
EP4525866A1 (en) * 2022-05-18 2025-03-26 Pliant Therapeutics, Inc. Stabilization of integrin inhibitors
CN120731091A (zh) 2022-12-14 2025-09-30 阿尔尼拉姆医药品有限公司 用于肝外递送的α-Vβ-6(αvβ6)整合素配体
WO2025259747A2 (en) 2024-06-12 2025-12-18 Alnylam Pharmaceuticals, Inc. Dystrophy myotonic protein kinase (dmpk) irna compositions and methods of use thereof
WO2025259743A1 (en) 2024-06-12 2025-12-18 Alnylam Pharmaceuticals, Inc. Dual conjugate compounds for extrahepatic delivery

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001024797A1 (en) * 1999-10-04 2001-04-12 Merck & Co., Inc. Integrin receptor antagonists
WO2005082889A1 (en) * 2004-02-18 2005-09-09 Janssen Pharmaceutica N.V. Piperidinyl targeting compounds that selectively bind integrins
WO2014154725A1 (en) * 2013-03-28 2014-10-02 Glaxosmithkline Intellectual Property Development Limited Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999030709A1 (en) 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
ES2241192T3 (es) 1997-12-17 2005-10-16 MERCK & CO., INC. (A NEW JERSEY CORP.) Antagonistas del receptor de integrina.
PT1187592E (pt) 1999-06-02 2007-10-19 Merck & Co Inc Antagonistas dos receptores de integrina alfa v
JP2003502373A (ja) 1999-06-23 2003-01-21 メルク エンド カムパニー インコーポレーテッド インテグリン受容体アンタゴニスト
CZ20021508A3 (cs) 1999-11-08 2002-10-16 Merck & Co., Inc. Způsob výroby imidazolidinonových derivátů
JP2004511434A (ja) 2000-06-15 2004-04-15 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
DE60126496T2 (de) 2000-07-26 2007-11-15 Merck & Co., Inc. Alpha v integrin-rezeptor-antagonisten
AU2001290772A1 (en) 2000-09-14 2002-03-26 Merck And Co., Inc. Alpha v integrin receptor antagonists
JP2004517853A (ja) 2001-01-03 2004-06-17 メルク　エンド　カムパニー　インコーポレーテッド 歯周病の治療方法及び治療用組成物
DE10112771A1 (de) 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta¶6¶
BR0317600A (pt) 2002-12-20 2005-11-29 Pharmacia Corp ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina
US6932865B2 (en) 2003-04-11 2005-08-23 Lockheed Martin Corporation System and method of making single-crystal structures through free-form fabrication techniques
RS53151B (sr) 2007-03-23 2014-06-30 Amgen Inc. 3-supstituisani derivati hinolina ili hinoksalina i njihova upotreba kao inhibitora fosfatidilinozitol 3-kinaze (pi3k)
US20100311736A1 (en) 2007-10-22 2010-12-09 Glaxosmithkline Llc Pyridosulfonamide derivatives as p13 kinase inhibitors
WO2011111880A1 (ko) 2010-03-08 2011-09-15 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
WO2015048819A1 (en) 2013-09-30 2015-04-02 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
KR102647026B1 (ko) 2015-02-19 2024-03-12 사이플루어 라이프 사이언시즈, 인크 플루오르화 테트라히드로나프티리디닐 노난산 유도체 및 이의 용도
CA2981371A1 (en) 2015-03-10 2016-09-15 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
GB201604589D0 (en) 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604681D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001024797A1 (en) * 1999-10-04 2001-04-12 Merck & Co., Inc. Integrin receptor antagonists
WO2005082889A1 (en) * 2004-02-18 2005-09-09 Janssen Pharmaceutica N.V. Piperidinyl targeting compounds that selectively bind integrins
WO2014154725A1 (en) * 2013-03-28 2014-10-02 Glaxosmithkline Intellectual Property Development Limited Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107823208A (zh) * 2017-10-25 2018-03-23 南京多宝生物科技有限公司 吗啉类化合物在制备治疗和预防肾纤维化药物中的应用
CN108208177A (zh) * 2017-11-28 2018-06-29 上海交通大学医学院附属新华医院 含丁酸类化合物的组合物及其应用

Also Published As

Publication number Publication date
JP6665169B2 (ja) 2020-03-13
US10000489B2 (en) 2018-06-19
TW201629057A (zh) 2016-08-16
BR112017006253A2 (pt) 2017-12-12
AR101995A1 (es) 2017-01-25
UY36315A (es) 2016-04-29
US20170298063A1 (en) 2017-10-19
KR20170063590A (ko) 2017-06-08
EP3197893A1 (en) 2017-08-02
JP2017528503A (ja) 2017-09-28
ES2704525T3 (es) 2019-03-18
WO2016046226A1 (en) 2016-03-31
GB201417011D0 (en) 2014-11-12
AU2015320859A1 (en) 2017-03-09
CA2962326A1 (en) 2016-03-31
EP3197893B1 (en) 2018-10-24
RU2017114346A (ru) 2018-11-02

Similar Documents

Publication Publication Date Title
CN107074849A (zh) 新的化合物
CN107074848B (zh) 吡咯烷化合物
KR101896599B1 (ko) 브로모도메인 억제제로서 유용한 테트라하이드로퀴놀린 유도체
TWI558704B (zh) 4-(8-甲氧基-1-(1-甲氧基丙-2-基)-2-(四氫-2H-吡喃-4-基)-1H-咪唑并[4,5-c]喹啉-7-基)-3,5-二甲基異噁唑及其用途
CN108699036A (zh) 化合物(s)-4-((s)-3-氟-3-(2-(5,6,7,8-四氢-1,8-萘啶-2-基)乙基)吡咯烷-1-基)-3-(3-(2-甲氧基乙氧基)苯基)丁酸(1:1)柠檬酸盐
CN108395452A (zh) 作为钠通道调节剂的吡啶酮酰胺的前药
JP2019509305A (ja) インテグリンアンタゴニストとしてのナフチリジン
CN105102450A (zh) 作为PERK抑制剂的新颖的N-(2，3-二氢-1H-吡咯并[2，3-b]吡啶-5-基)-4-喹唑啉胺和N-(2，3-二氢-1H-吲哚-5-基)-4-喹唑啉胺衍生物
TWI894443B (zh) 選擇性雌激素受體降解劑
CN116444499A (zh) 一种含4-喹唑啉酮的苯丙氨酸类衍生物及其制备方法与应用
CN111499639A (zh) 嘧啶酮衍生物及其在制药中的应用
WO2023168830A1 (zh) 一种hemtac小分子降解剂及其应用
WO2023116915A1 (zh) AChE/SERT双靶点抑制剂及其制备方法和用途
CN103242218B (zh) N-取代哌可酸衍生物及其制备方法与应用
HK1234041B (en) Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of e.g. fibrotic diseases
HK1234041A1 (en) Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of e.g. fibrotic diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170818

WD01 Invention patent application deemed withdrawn after publication